Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Pevifoscorvir · ALG-000184

Small molecule · developed by Aligos Therapeutics

Phase 2 Most advanced trial

ALGS Developer

2 Registered trials

What is Pevifoscorvir?

Pevifoscorvir sodium (ALG-000184) is given as a single oral dose in a trial in chronic hepatitis B infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: ALG-000184
Drug type: Small molecule
Therapy area: Infectious disease
Developer: Aligos Therapeutics (ALGS)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: G9Q8YSG7DD

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06963710	Phase 2	Chronic Hepatitis B Infection	Active not recruiting	ALGS
NCT07342881	Phase 1	Chronic Hepatitis B Infection	Completed	ALGS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Hepatitis B Infection

More from Aligos Therapeutics

ALG-010133 Phase 1 ALG-020572 Phase 1 ALG-055009 Phase 2 ALG-097558 Phase 1 ALG-125755 Phase 1

Sources

ClinicalTrials.gov NCT07342881

Updated Oct 11, 2026. Something wrong or missing? Report it on the ALGS page.

Follow ALGS, the company behind Pevifoscorvir

See ALGS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ALGS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z